Avalanche Biotechnologies Inc  

(Public, NASDAQ:AAVL)   Watch this stock  
Find more results for Paul Wachter
34.69
-2.11 (-5.73%)
Mar 3 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 34.63 - 36.91
52 week 22.00 - 62.48
Open 36.80
Vol / Avg. 279,607.00/384,718.00
Mkt cap 913.31M
P/E     -
Div/yield     -
EPS -1.02
Shares 24.84M
Beta     -
Inst. own 64%
Mar 10, 2015
Avalanche Biotechnologies Inc at the Barclays Global Healthcare Conference - 2:30PM EDT - Add to calendar
Mar 4, 2015
Avalanche Biotechnologies Inc at the Cowen and Company 35th Annual Health Care Conference - 8:40AM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -4047.06% -1099.17%
Operating margin -3892.16% -1067.71%
EBITD margin - -547.50%
Return on average assets -29.83% -717.34%
Return on average equity -47.57% -
Employees 26 -
CDP Score - -

Address

1035 O?Brien Drive, Suite A
MENLO PARK, CA 94025
United States - Map
+1-650-2726269 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Avalanche Biotechnologies, Inc. (Avalanche) is clinical-stage biotechnology company. The Company is focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. The Company operates through a single segment, being the business of developing and commercializing therapeutics. Avalanche's Ocular BioFactory platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. The Company�s lead product candidate, AVA-101 is used for the treatment of wet age-related macular degeneration (AMD). The Company�s AVA-201 is a next generation anti-VEGF gene therapy product candidate, which is being developed for the prevention of wet AMD. In addition, Avalanche�s AVA-311 is being developed for the treatment of Juvenile X-linked Retinoschisis (XLRS).

Officers and directors

Mark S. Blumenkranz M.D. Chairman of the Board, Co-Founder
Age: 63
Bio & Compensation  - Reuters
Thomas W. Chalberg Jr., Ph.D. President, Chief Executive Officer, Director
Age: 36
Bio & Compensation  - Reuters
Steven D. Schwartz M.D. Co-Founder, Director
Age: 52
Bio & Compensation  - Reuters
Linda C. Bain CPA Chief Financial Officer, Treasurer
Age: 43
Bio & Compensation  - Reuters
Hans P. Hull J.D. Senior Vice President - Legal and Corporate Development
Age: 39
Bio & Compensation  - Reuters
Roman G Rubio M.D. Senior Vice President and Head - Translational Medicine
Bio & Compensation  - Reuters
Mehdi Gasmi Ph.D. Vice President - Pharmaceutical Development
Age: 47
Bio & Compensation  - Reuters
Samuel B. Barone M.D. Chief Medical Officer
Age: 40
Bio & Compensation  - Reuters
John P. McLaughlin Director
Bio & Compensation  - Reuters
Paul D. Wachter Director
Age: 57
Bio & Compensation  - Reuters